Liberum acts as Sole Bookrunner and Broker on the £80.7m AIM IPO of Aptamer Group PLC raising £10.8m

We are pleased to announce that Liberum has successfully raised £10.8m in connection with the AIM IPO of Aptamer Group PLC. The shares were admitted to trading today, 22 December 2021.

Logo 2

Aptamer Group PLC (“Aptamer” or the “Group”) is a leader in the provision of aptamer selection services and the development of aptamer-based reagents. The Group solves intractable problems for biotech and big pharma by developing molecular binders called aptamers, which are an alternative to antibodies. Led by an experienced team, Aptamer has developed a novel, proprietary aptamer technology, known as Optimer® binders, which offer further performance and commercial benefits in addition to those of standard aptamers.

On Admission, the market capitalisation of the Company was approximately £80.7 million. The Placing raised gross proceeds of £10.8 million for the Company and attracted strong support from high quality institutional investors.

The net proceeds of the Placing, will be used for the following: to assist in scale-up and automation of the business; to develop novel nucleotide chemistries; for commercial expansion and service development and to continue to strengthen the Group's working capital.

Liberum acted as Sole Bookrunner on the IPO, and is retained as Sole Broker to the Company post Admission.

Liberum Team

Board – Bidhi Bhoma

Investment Banking – Richard Lindley, John Fishley, Ben Cryer, William Hall, Cara Murphy, Anthony Schia

Sales – Alistair Smallwood, Oliver Baxendale

Research – Alistair Campbell

Legal – Alice Foster

CIR – Nicole Barbour

Settlement – Rob Simpson, Mark Proctor

Sales Trading – Mark O’Hara

New York

Our offices


Ropemaker Place, Level 12 25 Ropemaker Street London EC2Y 9LY

New York

20th Floor 575 Fifth Avenue New York NY 10017